Celiac Artery Mesenteric Fat Measurement with Endosonography (CAMEUS) Reliably Correlates with Obesity and Related Comorbidities

Overview

Journal Gastroenterol Rep (Oxf)

Specialty Gastroenterology

Date 2024 Apr 29

PMID 38681751

Authors

Fateh Bazerbachi

Serge Baroud

Michael J Levy

Daniel B Maselli

Eric J Vargas

Aliana Bofill-Garcia

Ryan J Law

Vinay Chandrasekhara

Andrew C Storm

Ferga C Gleeson

Elizabeth Rajan

Prasad G Iyer

Kymberly D Watt

Barham K Abu Dayyeh

Affiliations

Soon will be listed here.

Abstract

Background: Visceral fat represents a metabolically active entity linked to adverse metabolic sequelae of obesity. We aimed to determine if celiac artery mesenteric fat thickness can be reliably measured during endoscopic ultrasound (EUS), and if these measurements correlate with metabolic disease burden.

Methods: This was a retrospective analysis of patients who underwent celiac artery mesenteric fat measurement with endosonography (CAMEUS) measurement at a tertiary referral center, and a validation prospective trial of patients with obesity and nonalcoholic steatohepatitis who received paired EUS exams with CAMEUS measurement before and after six months of treatment with an intragastric balloon.

Results: CAMEUS was measured in 154 patients [56.5% females, mean age 56.5 ± 18.0 years, body mass index (BMI) 29.8 ± 8.0 kg/m] and was estimated at 14.7 ± 6.5 mm. CAMEUS better correlated with the presence of non-alcoholic fatty liver disease (NAFLD) ( = 0.248, <0.001) than BMI ( = 0.153, <0.001), and significantly correlated with metabolic parameters and diseases. After six months of intragastric balloon placement, the prospective cohort experienced 11.7% total body weight loss, 1.3 points improvement in hemoglobin A1c (=0.001), and a 29.4% average decrease in CAMEUS (-6.4±5.2 mm, <0.001). CAMEUS correlated with improvements in weight ( = 0.368), aspartate aminotransferase to platelet ratio index ( = 0.138), and NAFLD activity score ( = 0.156) (all <0.05).

Conclusions: CAMEUS is a novel measure that is significantly correlated with critical metabolic indices and can be easily captured during routine EUS to risk-stratify susceptible patients. This station could allow for EUS access to sampling and therapeutics of this metabolic region.

References

Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K . The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005; 143(10):722-8. DOI: 10.7326/0003-4819-143-10-200511150-00009. View

Kissebah A, Krakower G . Regional adiposity and morbidity. Physiol Rev. 1994; 74(4):761-811. DOI: 10.1152/physrev.1994.74.4.761. View

Noureddin M, Lam J, Peterson M, Middleton M, Hamilton G, Le T . Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013; 58(6):1930-40. PMC: 4819962. DOI: 10.1002/hep.26455. View

Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View

Bazerbachi F, Haffar S, Sawas T, Vargas E, Kaur R, Wang Z . Fluid-Filled Versus Gas-Filled Intragastric Balloons as Obesity Interventions: a Network Meta-analysis of Randomized Trials. Obes Surg. 2018; 28(9):2617-2625. DOI: 10.1007/s11695-018-3227-7. View

Bazerbachi F, Vargas Valls E, Abu Dayyeh B . Recent Clinical Results of Endoscopic Bariatric Therapies as an Obesity Intervention. Clin Endosc. 2017; 50(1):42-50. PMC: 5299988. DOI: 10.5946/ce.2017.013. View

Yin Z, Murphy M, Li J, Glaser K, Mauer A, Mounajjed T . Prediction of nonalcoholic fatty liver disease (NAFLD) activity score (NAS) with multiparametric hepatic magnetic resonance imaging and elastography. Eur Radiol. 2019; 29(11):5823-5831. PMC: 6751038. DOI: 10.1007/s00330-019-06076-0. View

Goh V, Tain C, Tong T, Mok H, Wong M . Are BMI and other anthropometric measures appropriate as indices for obesity? A study in an Asian population. J Lipid Res. 2004; 45(10):1892-8. DOI: 10.1194/jlr.M400159-JLR200. View

Poynard T, Lenaour G, Vaillant J, Capron F, Munteanu M, Eyraud D . Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis. Clin Gastroenterol Hepatol. 2012; 10(6):657-63.e7. DOI: 10.1016/j.cgh.2012.01.023. View

10.

Caussy C, Reeder S, Sirlin C, Loomba R . Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials. Hepatology. 2018; 68(2):763-772. PMC: 6054824. DOI: 10.1002/hep.29797. View

11.

Bloomgarden Z . American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. Diabetes Care. 2003; 26(4):1297-303. DOI: 10.2337/diacare.26.4.1297. View

12.

Bazerbachi F, Haffar S, Wang Z, Cabezas J, Arias-Loste M, Crespo J . Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. Clin Gastroenterol Hepatol. 2018; 17(1):54-64.e1. DOI: 10.1016/j.cgh.2018.08.069. View

13.

Nickel F, Tapking C, Benner L, Sollors J, Billeter A, Kenngott H . Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Disease in a Prospective Study with 1-Year Follow-up : BariScan Study. Obes Surg. 2017; 28(5):1342-1350. DOI: 10.1007/s11695-017-3012-z. View

14.

Bazerbachi F, Vargas E, Matar R, Storm A, Mounajjed T, Topazian M . EUS-guided core liver biopsy sampling using a 22-gauge fork-tip needle: a prospective blinded trial for histologic and lipidomic evaluation in nonalcoholic fatty liver disease. Gastrointest Endosc. 2019; 90(6):926-932. DOI: 10.1016/j.gie.2019.08.006. View

15.

. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363(9403):157-63. DOI: 10.1016/S0140-6736(03)15268-3. View

16.

Sasaki A, Nitta H, Otsuka K, Umemura A, Baba S, Obuchi T . Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments. Front Endocrinol (Lausanne). 2014; 5:164. PMC: 4209858. DOI: 10.3389/fendo.2014.00164. View

17.

Hales C, Carroll M, Fryar C, Ogden C . Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018. NCHS Data Brief. 2020; (360):1-8. View

18.

Guarner V, Rubio-Ruiz M . Low-grade systemic inflammation connects aging, metabolic syndrome and cardiovascular disease. Interdiscip Top Gerontol. 2014; 40:99-106. DOI: 10.1159/000364934. View

19.

Subichin M, Clanton J, Makuszewski M, Bohon A, Zografakis J, Dan A . Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery. Surg Obes Relat Dis. 2015; 11(1):137-41. DOI: 10.1016/j.soard.2014.06.015. View

20.

Abu Dayyeh B, Maselli D, Rapaka B, Lavin T, Noar M, Hussan H . Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. Lancet. 2021; 398(10315):1965-1973. DOI: 10.1016/S0140-6736(21)02394-1. View